CAR T, immunotherapy bring new hope for multiple myeloma patients – Medical Xpress
Medical Xpress |
CAR T, immunotherapy bring new hope for multiple myeloma patients
Medical Xpress Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other … ‘Unheard of’ responses to bluebird CAR–T therapy seen in myeloma studyReuters #ASH17: The BCMA-targeted CAR–T bb2121 from bluebird and Celgene takes a star turn in the spotlightEndpoints News CAR T, immunotherapy bring new hope for multiple myeloma patientsEurekAlert (press release) |
News-Medical.net |
CAR T cell therapy shows long-lasting remissions in non-Hodgkin’s lymphoma patients
News-Medical.net In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah™ (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin’s lymphoma (NHL) patients. Results from a … Responses with CAR T-cell therapy appear durable for non-Hodgkin lymphomaHealio Phase 2 CAR–T study reports significant remission rates at 15-month follow upMedical Xpress New Data for FDA-Approved CAR T Therapy Show Significant …Markets Insider OncLive all 4 news articles » |
|
Drug improves disease-free, overall survival after hematopoietic stem cell transplants
News-Medical.net Results from a phase 2 clinical trial, presented by Seattle Children’s Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft … |